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1. Introduction
In the embryonic period, the nervous system originates from a layer of 
 ectodermal cells which is called neuroectoderm. The neuroectoderm extends along 
the axis of the body to form the neural plate. The latter, turns inward and sur-
rounds itself of neural folds, which then merge together giving life to the neural 
tube that will develop all the components of the central nervous system and the 
spinal cord. Finally, from the posterior portion of the neural tube, specialized cells 
will separate to form the neural crest. Various differentiated cell types, tissues and 
organs develop from neural crest cells, the mechanisms for this are not well known. 
However, these cells are multipotent and their subsequent specialization it could be 
conditioned by the activity of particular genes and by the microenvironment into 
which they migrate [1]. Hence, neural crest cells have a multipotent differentiation 
potential. From these cells originate neurons and glial cells, melanocytes, Schwann 
cells, parafollicular cells of the thyroid, cells of the adrenal medulla, endothelial 
cells of large vessels and some components of the connective and skeletal tissue 
of the head [2] (Figure 1). Based on these concepts, the tumors that develop from 
the cells of the neural crest represent a very varied and heterogeneous group of 
neoplasms, these can affect different body locations where the neural crest cells-
derived are normally present. However, neural crest stem cells are also present in 
some adult tissues that normally do not originate from the neural crest, such as 
skin and bone marrow [3]. Heterogeneity of tumors originating from neural crest 
cells is confirmed by the fact that some of them can arise in both peripheral sites 
or in the central nervous system, while others are specific to the central nervous 
system or affect only other peripheral locations. Neural crest cell-derived tumors 
can be grouped into: tumors of peripheral and cranial nerves, melanocytic tumors, 
peripheral neuroblastic tumors, embryonal tumors of the central nervous system, 
paraganglioma group, and other tumors of neural crest origin. Most of these are 
sporadic, some can be hereditary (hereditary paraganglioma-pheochromocytoma 
syndrome, von Hippel–Lindau disease, neurofibromatosis, schwannomatosis, and 
multiple neuroendocrine neoplasia (MEN I). Pheochromocytoma/Paraganglyoma 
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and neuroblastoma are the most common neural crest-derived tumors in adults and 
children, respectively. These neoplasm are both associated with significant morbid-
ity and mortality.
2. Sympatho-adrenal lineage neoplasms
Neural crest cell-derived of the truncal area after a ventral migration reach the 
vertebral parasympathetic ganglia of the trunk and the chromaffin cells secreting 
catecholamines of the adrenal medulla and paraganglia [4, 5]. Tumors arising from 
the cell line involving the sympathetic ganglia can have variable aggressiveness, 
they can develop from neuroblastomas to ganglioneuromas. Pheochromocytomas 
and paragangliomas are tumors that develop from neural crest cells that have 
migrated into the adrenal medulla and paraganglia, they can occur sporadically or 
within familial syndromes.
2.1 Neuroblastoma
Neuroblastoma is the most frequent extracranial malignancy in children, 
accounting for 8–10% of pediatric malignancy and with a mortality of 15%. About 
38% of primary tumors are located in the adrenal medulla and 1–2% of newly 
diagnosed neuroblastomas are related to the family history of the disease [6]. At 
diagnosis, 50% of patients present with lymph node, liver, cortical bone and bone 
marrow metastases. Due to the presence of an expanding mass, compression of 
nearby vascular and neuronal structures may occur. The disease can also manifest 
itself with paraneoplastic syndromes including opsoclonus-myoclonus and intrac-
table watery diarrhea, due to autoimmune cerebellar destruction or production 
of vasoactive intestinal peptide, respectively [6]. The prognosis is varied, rang-
ing from spontaneous regressions of the disease, neuroblastoma can change into 
more differentiated ganglioneuromas or have a clearly aggressive course with poor 
survival [7]. Tumor regression is an unknown process, but may be due to expression 
of the nerve growth factor (NGF) receptor TrkA, which promotes differentiation in 
Figure 1. 
Segments of neural crest with relative adult tissues and pathologies derivate [2].
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the presence of NGF and apoptosis in its absence, as described below. Familial type 
of neuroblastoma is quite rare, it is associated with mutated PHOX2B. Its sporadic 
form is also frequently associated with the mutated PHOX2B, but the most signifi-
cant lesion is MYCN amplification. The molecular and genetic characteristics of 
neuroblastoma are complex and are responsible for the clinical course and progno-
sis of the disease. The presence of MYCN amplification, chromosomal abnormali-
ties, DNA ploidy, degree of stromal differentiation, tumor stage, and patient age all 
impacting outcome [8, 9]. This tumor characterized by a remarkable plasticity and 
by its wide spectrum of presentation remains a stimulating and fascinating subject 
for both doctors and researchers who deal with it in a specialized way.
2.2 Pheocromocytoma and paraganglioma
Pheochromocytoma and paraganglioma (PPGL) have a prevalence in autopsy 
studies of 0.05%, which indicates that during the life of many people it is not 
diagnosed [10, 11]. Amar in 2005 reports an average delay in diagnosis of about 
3 years [12]. Their prevalence varies from 0.2% to 0.6% in hypertensive patients 
to less than 0.05% in the general population, with an annual incidence of about 
5 cases per million per year. Two recent retrospective series reported that two 
thirds were discovered as incidentalomas [13, 14]. PPGL are tumors originating 
from tissues arising from the neural crest respectively in the paraxial autonomic 
ganglia or in the chromaffin cells of the adrenal medulla, these tumors are highly 
vascularized. PPGL arise from tissues derived from the neural crest, respectively 
in the paraxial autonomic ganglia or in the chromaffin cells of the adrenal medulla. 
Pheochromocytoma and truncal paraganglioma arising from the sympatho-adrenal 
lineage cells secrete cathecholamines and are highly vascularized. Clinical symp-
toms can be characterized by tachycardia, hypertension, and a high risk for stroke 
[15]. In contrast, paragangliomas arising from the parasympathic ganglia are gener-
ally nonsecretory and are most commonly found in the head and neck [16, 17], 
these tumors present as a mass and cause symptoms from compression of adjacent 
vascular or neuronal structures. In 35% of cases, PPGLs are caused by autosomal 
dominant germ-line mutations in the succinate dehydrogenase genes or they are 
found in multitumor syndromes such as neurofibromatosis type 1and MEN2A/2B 
[18, 19]. Compared to sporadic cases, patients with hereditary forms are younger, 
with a higher incidence of metastases and a more aggressive disease [20]. Familial 
syndromes are associated with loss-of-function mutations in the SDH mitochon-
drial enzyme complex II genes, including the four subunits of SDH and SDHAF2, 
which flavinates SDHA [21].
3. Future perspectives
The neural crest is an example of a unique and transient developmental struc-
ture, endowed with plasticity, proliferative capacity, migratory capacity, and 
remarkable self-limitation. Its biological and behavioral similarity of the malignant 
metastatic cell has led to make comparisons between them and to develop the idea 
that mutual cancer development programs for invasion and proliferation can be 
exploited [22] (Figure 2). In neuroblastoma, clinical maturation from aggressive 
“precursor-like” lesions to well-differentiated ganglioneuromas speaks to the plas-
ticity of the NC and the normal developmental limitation of pluripotency. Based on 
these theories and shares regarding the development of the neural crest and cancer, 
we can understand the importance of studying these growth mechanisms and how 
fundamental these implications are for the treatment of malignancy. Cancer is 
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usually treated surgically, but also in a multidisciplinary way with chemotherapy 
and radiotherapy. Each of these disciplines has led to many improvements in the 
survival of these patients but also to an increase in morbidity. Designing targeted 
therapies is a priority in order to achieve more effective treatment with less col-
lateral damage. Azmi [23] in 2013 and Muller [24] in 2014 tested the therapeutic 
potential of Snail and c-Myc inhibitory molecules, respectively. Also Chua [25] in 
2012 carried out a study aimed at identifying inhibitors of epithelial – mesenchymal 
transition in order to inhibit cell invasiveness and metastasis. The future direction 
should point to a complete identification of these factors which are very important 
for both neural crest development and tumor growth and metastasis, including 
cell survival, proliferation, motility, invasiveness, and differentiation. Only a more 
complete understanding of molecular similarities, we will then be poised to develop 
targeted therapies aimed at modulating those processes that are critical to tumor 
growth and metastasis. Testing potential new anti-cancer drugs is also an important 
future step, but is often slow, expensive, and limited to cultured cancer cells or arti-
ficial tumor models. NC development study can certainly represent a fundamental 
topic through which to develop new strategies and new drugs for cancer therapy.
In this book we want to offer the reader some elements of epidemiology, genet-
ics and treatment of pheochromocytoma, paraganglioma and neuroblastoma. Our 
work does not reach definitive conclusions but aims to provide elements of knowl-
edge regarding non-common neoplasms that have a unique denominator: they are 
Neural crest cell-derived tumors.
Figure 2. 
Cancer metastasis and neural crest cell migration exhibit striking similarities [22].
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